ReviewMolecular and cellular biochemistry2023
Impairment of insulin signaling pathway PI3K/Akt/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective review.
Review in Molecular and cellular biochemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
142 citing papers in PubMed, 2 syntheses or guidelines pooled it, 192 citations in OpenAlex.
- Efficacy and safety of PI3K inhibitors combined with fulvestrant for HR+/HER2- advanced breast cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Cellular and Molecular Pathophysiology of Gestational Diabetes.International journal of molecular sciences · 2024Pooled it
- Programmed cell death in metabolic syndrome: From molecular mechanisms to therapeutic strategies (Review).International journal of molecular medicine · 2026Review
- Fgl-1 promotes the progression of endometrial adenocarcinoma through PI3K/AKT signal pathway.Medical oncology (Northwood, London, England) · 2026Article
- Immunometabolism in Obesity-Associated Type 2 Diabetes: Molecular Mechanisms and Emerging Therapeutic Targets.International journal of molecular sciences · 2026Review
- Immune checkpoints and immunoregulation in metabolic diseases and cancers: pathological mechanisms and therapeutic potential.Signal transduction and targeted therapy · 2026Review
- Mechanistic Pathways of Wound Healing: From Hemostasis to Scar-Free Regeneration.Cell biochemistry and function · 2026Review
- Phytochemical Profiling, In Vitro Bioactivity, and Network Pharmacology ofMolecules (Basel, Switzerland) · 2026Article
- Brain insulin resistance as a driver of proteinopathy in neurodegeneration: from cell-type-specific mechanisms to targeted therapeutics.Translational neurodegeneration · 2026Review
- Neurons Die Not by One Hit, but by Signaling Convergence.Molecular neurobiology · 2026Review
- Computational discovery of fenugreek-paitan-turmeric (FPT) bioactive compounds targeting SGLT2 and DPP-4 for glucose homeostasis regulation.Journal of Taibah University Medical Sciences · 2026Article
- Neurodegenerative diseases and immune system: From pathogenic mechanism to therapy.Neural regeneration research · 2026Article
- Integrating Peptidomics, Network Pharmacology, Molecular Docking, and In Vitro α-Glucosidase Inhibition Assays to Explore the Hypoglycemic Activity and Action Mechanisms of Chinese Yam Peptides.Foods (Basel, Switzerland) · 2026Article
- CCDC137 affects sorafenib resistance in hepatocellular carcinoma cells by activating the AKT/mTOR signaling pathway.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Peptide Hormones in Appetite Regulation: A Complex Network.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Phytochemical Profiling and Subacute Toxicity Assessment of Miliusa nilagirica Carbinolic Extract in Murine Models With Antioxidant and Antidiabetic Potential.Applied biochemistry and biotechnology · 2026Article
- The Effect of Resistance Training and Ursolic Acid on the PI3K-AKT-mTOR Pathway in Aged Diabetic Rats: A Comparative Study.Aging medicine (Milton (N.S.W)) · 2026Article
- Rhizomes as Multi-Target Pharmacological Platforms Against Tauopathy: Neuro-Metabolic Crosstalk, Drug-Likeness, and Translational Challenges.Pharmaceuticals (Basel, Switzerland) · 2026Review
- CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.Cardiovascular diabetology · 2026Article
- Bioavailability enhancement and neuropharmacological effects of Dauricine under intranasal administration to improve cognitive impairment via PI3K/AKT/mTOR pathway.Drug delivery and translational research · 2026Article
82 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin resistance is common in type 2 diabetes mellitus (T2DM), neurodegenerative diseases, cardiovascular diseases, kidney diseases, and polycystic ovary syndrome. Impairment in insulin signaling pathways, such as the PI3K/Akt/mTOR pathway, would lead to insulin resistance. It might induce the synthesis and deposition of advanced glycation end products (AGEs), reactive oxygen species, and reactive nitrogen species, resulting in stress, protein misfolding, protein accumulation, mitochondrial dysfunction, reticulum function, and metabolic syndrome dysregulation, inflammation, and apoptosis. It plays a huge role in various neurodegenerative diseases like Parkinson's disease, Alzheimer's disease, Huntington's disease, and Amyloid lateral sclerosis. In this review, we intend to focus on the possible effect of insulin resistance in the progression of neurodegeneration via the impaired P13K/Akt/mTOR signaling pathway, AGEs, and receptors for AGEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.